Loading...
XLON
FUM
Market cap4mUSD
Dec 05, Last price  
1.02GBP
1D
-6.42%
1Q
-89.32%
Jan 2017
-98.18%
IPO
-98.62%
Name

Futura Medical PLC

Chart & Performance

D1W1MN
XLON:FUM chart
P/E
2.40
P/S
0.22
EPS
0.00
Div Yield, %
Shrs. gr., 5y
8.71%
Rev. gr., 5y
237.55%
Revenues
14m
+349.09%
2,000015,000150,00050,000125,000158,00075,000370,90243,92929,476170,362362,727031,7780003,100,96813,926,122
Net income
1m
P
-1,936,000-1,777,000-2,254,000-1,935,000-1,393,000-1,091,000-1,815,000-2,176,649-2,208,332-2,997,881-5,081,442-3,697,113-3,900,284-5,880,576-8,919,290-2,408,377-4,957,711-5,846,495-6,512,8991,293,010
CFO
438k
-23.12%
-2,125,000-1,852,000-2,282,000-1,971,000-1,318,000-1,047,000-1,836,000-1,940,808-2,013,958-3,066,726-5,363,850-3,297,994-4,174,807-4,708,035-6,656,247-4,543,355-3,873,270-5,775,346570,253438,411

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.
IPO date
Jul 10, 2006
Employees
12
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT